AAIF.L $206.00 -0.2421%
ROR.L $328.40 0.4281%
PCGU $150.89 0.0698%
AGGRU $10.20 0%
CRNC $23.66 0.8525%
SML.L $0.14 -7.6667%
AXON $201.01 -1.7522%
MPLS.L $47.00 9.3023%
TUB.BR $76.00 -0.3932%
CVCO $297.48 -1.1267%
2212.HK $0.21 0%
CATH.L $24.31 -1.78788%
FSTA $46.37 -0.1937%
TRG.L $150.00 0%
SBBA $24.85 -0.0201%
3613.HK $15.84 -1.2469%
ARLP $18.16 -1.7587%
FXI $27.76 -2.7505%
KURI $9.20 0%
SPAQ $6.46 0%
LESU.L $25.21 0%
IRMD $46.13 -0.1299%
CDMO $17.25 -2.2109%
RHI $66.62 -0.7893%
GDX $33.53 0.0149%
1927.HK $0.16 0%
SEC.L $309.50 2.1452%
1748.HK $2.62 0%
GTEC $1.19 -4.632%
DISCK $24.42 0%
SCS.L $172.84 0.9285%
SEB $3 783.20 -1.0346%
AUT.PA $83.12 0.0783%
MLACT.PA $1.20 13.2076%
1308.HK $12.92 -3.2934%
RYA.L $14.42 0%
BUL $33.17 -0.636%
PHG.PA $149.11 0.1733%
THG $118.71 -0.5904%
VRA $5.35 0.0936%
1977.HK $1.35 -3.5714%
SCT.L $1 322.00 -1.1958%
SNPX $0.78 0%
HOLUU $13.65 0%
SCRF.L $104.50 0%
CRBP2.PA $18.30 -0.5326%
ESTR4.SA $69.00 6.1538%
MEOAU $10.40 0%
BRGE12.SA $9.89 6.3441%
HDIV $31.37 0%
SONY $94.53 1.4108%
SWC.L $158.00 0%
NKG $10.10 0%
VCBC.L $1.30 0%
0109.HK $0.09 0%
UEPS $4.74 0%
THQ $18.65 -0.7717%
ELMD $11.60 -2.351%
LVOXU $2.68 0%
0R1C.L $3.88 0.0904%
0342.HK $0.04 0%
DRVG.L $8.77 0.6603%
ARPO $2.20 0%
BH $183.32 0.1749%
JFWD $8.24 -1.8206%
0M40.L $0.37 5.4412%
HOLI $15.22 -1.9961%
LACQ $13.41 0%
FCIT.L $897.00 0.2235%
WEBS $21.11 4.4016%
D5IU.SI $0.02 0%
HYACW $0.68 0%
ETX $17.80 -0.1403%
QQ.L $371.40 0.8143%
0358.HK $12.60 -6.3893%
AEDAS.MC $13.68 -2.1459%
PLUS.L $1 519.00 -0.1315%
USSC.L $49.99 -0.07%
HON.L $159.07 0%
PHUN $0.61 -5.5797%
COF-PI $18.02 0.1111%
TRSX.L $27.24 -0.1466%
CP9G.L $51 760.00 0.0135%
FTHY $13.65 -0.5594%
2160.HK $2.18 -3.1111%
GIS $90.24 -0.0266%
DRUA $25.09 0%
IJJ $97.95 -0.8067%
LWSA3.SA $6.69 8.6039%
UNIT $3.62 -1.4986%
UTG.L $912.00 -1.5119%
XSPA $0.66 0%
0156.HK $0.10 0%
MDWT $25.79 0.1553%
STRRP $9.00 3.4483%
IHC $57.01 0%
Eng
Логотип
Eng
Лого

Inventiva S.A. IVA.PA

$2.40

+$0.02 (0.63%)
На 18:01, 12 мая 2023

Ранг: 3

Ранг - это оценка кредитоспособности корпорации.

Ключевые показатели

  • Marketcap

    100279396.00000000

  • week52high

    9.09

  • week52low

    1.88

  • Revenue

    12179000

  • P/E TTM

    0

  • Beta

    1.22137400

  • EPS

    -1.17000000

  • Last Dividend

    0.00000000

  • Next Earnings Date

    29 мар 2023 г. в 10:59

Описание компании

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of MPS VI subtype disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company has strategic collaboration with AbbVie for the treatment of autoimmune diseases; and Boehringer Ingelheim International GmbH for developing new treatments for idiopathic pulmonary fibrosis. Inventiva S.A. was founded in 2011 and is based in Daix, France.

Свежие комментарии

Оставьте свой голос

Анонимное голосование

Будет ли рост российского рынка к концу года?

  • Да

    87%

  • Нет

    12%

Проголосовал 8 человек